OpenAI Upgrades GPT-Rosalind With GPT-5.5 for Life Sciences
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
OpenAI Upgrades GPT-Rosalind With GPT-5.5 for Life Sciences
OpenAI has announced major new capabilities for GPT-Rosalind, its specialized AI model family designed specifically for life sciences research and enterprise-scale scientific workflows. The latest update combines the advanced reasoning, agentic coding, and tool-use capabilities of GPT-5.5 with domain-specific intelligence tailored for biotechnology, pharmaceutical research, genomics, medicinal chemistry, and experimental design. The move highlig…
OpenAI GPT-Rosalind Update Brings Advanced AI Drug Discovery and Genomics Research Capabilities
On June 3, 2026, OpenAI announced a significant update to its GPT-Rosalind model series, a specialized artificial intelligence system purpose-built for enterprise-scale life sciences research, drug discovery, genomics, and experimental biology. The new update integrates the advanced agentic coding and tool-use capabilities of GPT 5.5 with deeper model intelligence, specifically optimized for core drug discovery […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
